Secondly, our cohort only included patients with symptoms suggesting muscular or rheumatic disorders, and therefore, did not evaluate the prevalence of anti-cN1A in healthy subjects, which indeed was not one of our aims. This evidence concerns the gene NT5C1A and rheumatic disorder.